This trial is evaluating whether Bevacizumab will improve 1 primary outcome, 6 secondary outcomes, and 1 other outcome in patients with Peritoneal Malignant Mesothelioma. Measurement will happen over the course of From study entry to death from any cause, assessed up to 3 years.
This trial requires 66 total participants across 2 different treatment groups
This trial involves 2 different treatments. Bevacizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"There has been a significant improvement in average survival time and quality of life since the 1980s. Although many patients remain symptomatic for years after diagnosis, their symptoms often improve over time. Recent findings showed that surgery was not always necessary. Surgery should be considered only for those who are candidates for extrapleural pneumonectomy (EPP). For patients who are not surgical candidates, chemotherapy should be used as part of multimodality treatment. Patients with unresectable disease should receive palliative care." - Anonymous Online Contributor
"Bevacizumab is well tolerated in patients with metastatic malignancy. It does not seem to have a significant impact on serious adverse events or clinical outcomes. This trial was registered at www.anzctr.org.au/trial_view.aspx?ID=3000057." - Anonymous Online Contributor
"Clinical trials of bevacizumab have demonstrated that the drug has no effect on overall survival; however, more patients had metastatic disease when bevacizumab was given compared to placebo. When metastatic disease worsens, the patient's prognosis improves significantly. Data from a recent study shows that bevacizumab does not appear to increase overall survival in patients with recurrent or metastatic pancreatic cancer." - Anonymous Online Contributor
"When comparing ages across countries, we found that mean age of diagnosis was lowest in New Zealand at 56.5 yr and highest in Canada at 70 yr. Countries with a lower proportion of women, such as Belgium, France, Germany, Italy, Sweden, and Switzerland had an earlier mean age at diagnosis of 59 yr, whereas countries with a higher proportion of women, such as Australia, Spain, and the United Kingdom, had a later mean age at diagnosis of 63 yr." - Anonymous Online Contributor
"Clinical trials seem to offer little benefit to patients with recurrent disease after chemotherapy. However, they may improve survival in patients with localized disease, particularly those who have not received surgery as part of their initial treatment. Clinical trials for mesothelioma should focus on evaluating more effective systemic therapies." - Anonymous Online Contributor
"The overall findings suggest that this drug may improve QOL in those with recurrent/metastatic MEC. However, individual differences in baseline QOL may influence the impact of bevacizumab on QOL. Further research is required to confirm these findings and to investigate whether the magnitude of change in QOL, abnormalities detected during therapy, and the duration of bevacizumab therapy are associated with improved survival." - Anonymous Online Contributor
"Alcoholic beverage consumption is associated with an increased risk of developing mesothelioma. Smoking may increase the risk of developing mesothelioma. Asbestos is a common environmental carcinogen that is associated with mesothelioma. Specific types of asbestos are particularly hazardous." - Anonymous Online Contributor
"Mesothelioma is caused by asbestos exposure. There are many types of mesothelioma. The most common type is called sarcomatous mesothelioma. This form typically develops after asbestos exposure. Other forms of mesothelioma occur less often and include biphasic, desmoplastic, epithelioid, and clear cell and giant cell subtypes. These last three types appear more commonly in women. Desmoplastic and biphasic mesotheliomas are usually benign. Sarcomatous mesothelioma can progress to metastatic disease (cancer spreading to distant sites), even when the primary tumor has had a long period of dormancy as a result of treatment." - Anonymous Online Contributor
"Mesothelioma has several symptoms, which include a cough, shortness of breath, chest pain, weight loss, fever, fatigue, and night sweats.\n\nMesothelioma is also associated with other cancers of the respiratory tract, such as lung squamous cell carcinoma, small cell lung cancer, adenocarcinoma, adenosquamous carcinoma, and sarcomatoid carcinoma. Most metastatic cancers form in the brain, liver, or lymph nodes. Symptoms depend on where in the body the cancer is located.\n\nThe typical mesothelioma tumor usually appears as a mass on medical imaging techniques." - Anonymous Online Contributor
"In a recent study, no significant difference was seen in PFS between bevacizumab and placebo-treated patients in patients with malignant mesothelioma. This suggests that bevacizumab may prolong survival only in a subgroup of patients with recurrent disease who either do not have systemic metastasis or have distant metastases during adjuvant therapy." - Anonymous Online Contributor
"Survival rates for patients who develop metastatic disease are low, even for those whose primary disease has been successfully controlled. The behavior of mesothelioma cells is complex and multifactorial, and depends upon the type of cell involved, the location of origin within the body, and the stage of dissemination. Overall, survival rates for patients with localised disease have improved over time, although this may partly be due to earlier recognition and treatment." - Anonymous Online Contributor